As of 2024, 19 bispecific antibody drugs have been approved globally, with over 200 candidates in clinical development and an annual growth rate exceeding 30%. Current focus remains on oncology, while expanding into hematologic diseases, autoimmune disorders and other areas. Leveraging diverse structural formats (e.g., IgG-like, BiTE®), BsAbs enable synergistic targeting and immune cell bridging, demonstrating superior efficacy versus conventional therapies. Emerging technologies like BsAb-ADCs are driving applications in neurodegenerative diseases and beyond.

Sanyou Bio offers a validated collection of 73 reference BsAb covering major platforms (CrossMab, BiTE®, etc.), supporting end-to-end R&D from candidate screening to preclinical evaluation. SY-CRS-BsAb solutions accelerate development by addressing key technical challenges and improving efficiency.

SY-CRS-BsAb Isotype Distribution

SY-CRS-BsAb Target Distribution

Manufacturing Process

Quality Management System

SanYou Bio’s advanced antibody production system features high-end international equipment and full capabilities in plasmid construction, protein expression, and purification. Operating under GMP-grade host cells and Grade C+A cleanroom conditions, it follows 400+ standardized SOPs to ensure high-throughput, efficient delivery. All processes comply with ISO9001 and ISO27001, with strict quality control to guarantee antibody quality.